000 01594 a2200433 4500
005 20250515122721.0
264 0 _c20080730
008 200807s 0 0 eng d
022 _a1569-8041
024 7 _a10.1093/annonc/mdn194
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aEngert, A
245 0 0 _aTreatment of lymphocyte-predominant Hodgkin lymphoma.
_h[electronic resource]
260 _bAnnals of oncology : official journal of the European Society for Medical Oncology
_cJun 2008
300 _aiv45-6 p.
_bdigital
500 _aPublication Type: Comparative Study; Journal Article; Review
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xtherapeutic use
650 0 4 _aBleomycin
_xtherapeutic use
650 0 4 _aCombined Modality Therapy
650 0 4 _aDacarbazine
_xtherapeutic use
650 0 4 _aDisease-Free Survival
650 0 4 _aDoxorubicin
_xtherapeutic use
650 0 4 _aFemale
650 0 4 _aFollow-Up Studies
650 0 4 _aHodgkin Disease
_xclassification
650 0 4 _aHumans
650 0 4 _aLymphocytes
_xpathology
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aNeoplasm Staging
650 0 4 _aPrognosis
650 0 4 _aRadiotherapy
650 0 4 _aRetrospective Studies
650 0 4 _aTreatment Outcome
650 0 4 _aVinblastine
_xtherapeutic use
773 0 _tAnnals of oncology : official journal of the European Society for Medical Oncology
_gvol. 19 Suppl 4
_gp. iv45-6
856 4 0 _uhttps://doi.org/10.1093/annonc/mdn194
_zAvailable from publisher's website
999 _c18012238
_d18012238